Genzyme/Schering AG To Initiate Campath Phase III Trial For MS
This article was originally published in The Pink Sheet Daily
Executive Summary
Firms agree with FDA on Phase III plan despite suspension of Phase II program following three cases of severe idiopathic thrombocytopenic purpura.